Find the right fit for you - faster
Get tailored insights about working at CHAD Therapeutics in one quick step.
CHAD Therapeutics Snapshot
Finding the home oxygen market inhospitable, CHAD Therapeutics is looking for a friendlier reception as a sleep disorder company. It sold its oxygen conserver assets to Florida-based Inovo and some other oxygen equipment assets to Respironics; and it is using the money from the sales to pay off debt and develop devices for treating sleep disorders, a therapeutic category that includes conditions such as sleep apnea. Its oxygen conserver products, which it had been making since 1986, were devices that extended the life of home oxygen supplies for patients who require supplemental oxygen. The company has entered into Chapter 7 bankruptcy protection.
